Advertisement
Advertisement
TWST
Twist Bioscience Corporation Common Stock
47.92
USDSponsored
-0.92
-1.88%
Apr 10, 16:00 UTC -4
Closed
After-Market
48.78
+0.86
+1.81%
TWST Earnings Reports
Positive Surprise Ratio
TWST beat 18 of 30 last estimates.
60%
Next Report
Date of Next Report
Apr 30, 2026
Estimate for Q2 26 (Revenue/ EPS)
$109.81M
/-$0.48
Implied change from Q1 26 (Revenue/ EPS)
+5.89%
/-4.00%
Implied change from Q2 25 (Revenue/ EPS)
+18.34%
/-27.27%
Twist Bioscience Corporation Common Stock earnings per share and revenue
On Feb 02, 2026, TWST reported earnings of -0.50 USD per share (EPS) for Q1 26, missing the estimate of -0.43 USD, resulting in a -14.00% surprise. Revenue reached 103.70 million, compared to an expected 102.82 million, with a 0.86% difference. The market reacted with a +13.98% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 11 analysts forecast an EPS of -0.48 USD, with revenue projected to reach 109.81 million USD, implying an decrease of -4.00% EPS, and increase of 5.89% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
MiNK Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.83
Actual
-$0.55
Surprise
+33.64%
Kairos Pharma, Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.07
Surprise
-28.68%
Imunon, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.19
Actual
-$1.99
Surprise
-66.18%
Soligenix, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.57
Actual
-$0.28
Surprise
+50.98%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$12.24
Actual
-$8.00
Surprise
+34.64%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$5.19
Actual
-$10.15
Surprise
-95.50%
FAQ
What were Twist Bioscience Corporation Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Twist Bioscience Corporation Common Stock reported EPS of -$0.50, missing estimates by -14%, and revenue of $103.70M, 0.86% above expectations.
How did the market react to Twist Bioscience Corporation Common Stock's Q1 2026 earnings?
The stock price moved up 13.98%, changed from $41.07 before the earnings release to $46.81 the day after.
When is Twist Bioscience Corporation Common Stock expected to report next?
The next earning report is scheduled for Apr 30, 2026.
What are the forecasts for Twist Bioscience Corporation Common Stock's next earnings report?
Based on 11
analysts, Twist Bioscience Corporation Common Stock is expected to report EPS of -$0.48 and revenue of $109.81M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement